© 2021 MJH Life Sciences and Oncology Nursing News. All rights reserved.
© 2021 MJH Life Sciences™ and Oncology Nursing News. All rights reserved.
July 27, 2021
The FDA has approved the first immunotherapy, pembrolizumab (Keytruda), to treat patients with high-risk early-stage triple-negative breast cancer.
July 23, 2021
Study results have posited plinabulin as a potentially effective preventative and active therapy due to its unique mechanism of action.
June 27, 2021
Regardless of clinical risk, the survival prognosis of patients with early-stage breast cancer is high amongst those who have ultralow risk disease indicated by a 70-gene signature.
June 08, 2021
Sacituzumab govitecan, an antibody drug conjugate, maintained survival and response benefits over chemotherapy regimens.
June 04, 2021
Patients with BRCA1/2-mutant, early HER2-negative breast cancer at a high risk of recurrence saw a clinically meaningful benefit 1 year after standard of care when treated with olaparib.
May 28, 2021
Public health efforts must address new methods of cancer screening, an expert says.
May 10, 2021
A 9-week trastuzumab regimen may be favorable for patients with HER2-positive early breast cancer who have low and intermediate risk factors.
May 07, 2021
Each patient with breast cancer has a unique experience. Their survivorship care should reflect that.
April 30, 2021
It is well known that fear of recurrence is a major issue in the cancer community, but can genetic test results outlining risk impact those feelings?
April 28, 2021
In particular, patients reported improved knowledge in survivorship/surveillance and brain fog following the 6-week program.